Additional Samples Available Upon Request
Disease State Education
The scourge of Renal Cell Carcinoma.
Unwanted. Unbidden. Undetected.
Difficult. Damaging. Decade after decade, it devastates the lives of hundreds of thousands of patients. It’s a deeply personal battle against a powerful and persistent enemy.
We asked, “If not chemotherapy, not targeted therapy, not immunology therapy, not gene therapy, then what?” Why not disrupt the metabolism of cancer cells?
Simple observation. Extraordinary implications.
Corporate Manifesto
WE
WILL DELIVER AN UNPRECEDENTED BENEFIT
TIME TO DETECT. CONSIDER. CHOOSE.
FOR THE BEST CHANCE OF SUCCESSFUL TREATMENT
WILL
WAIT FOR NO ONE
BE AN R&D FORCE MULTIPLIER
INSPIRE CHANGE IN CLINICAL PRACTICE
FORGE DYNAMIC COLLABORATIONS
CONQUER
CURRENT LIMITATION AND CONSTRAINTS
SO TOMORROW WILL BE PROFOUNDLY BETTER
FOR PATIENT AND PHYSICIANS
WHOSE LIVES ARE AFFECTED BY
CANCER
TRANSFORMING THE FOUNDATIONAL
MOLECULAR INFORMATION TO ENABLE
PRECISION ONCOLOGY
WITH DATA
iCVA
Heart failure (HF) is a progressive disease.
Whether outpatient or inpatient, a heart failure diagnosis can signal the need for urgent action. Any recent hospitalization or urgent incident impacts prognosis and treatment.
-
Within 30 days of hospitalization, patients face a 2- to 3-fold higher risk of acute HF events.
-
HF patients who had been hospitalized within 30 days of initiation experienced the greatest benefits of our therapy.
Elevated NT-proBNP is a biomarker of cardiac wall stretch in HF.
-
Measurement of natriuretic peptide biomarkers is a Class IA recommendation for diagnosis and prognosis.
-
Elevated levels of NT-proBNP can be a sign of increased cardiac wall stretch or heart failure.
-
A decrease in NT-proBNP of >30% has been shown to be associated with reduced risk of CV death and HF hospitalization.
Device Communication
Continuous Glucose Monitors (CGMs) promise continuous monitoring and continuous accuracy. Current devices deliver continuous monitoring, alerting the wearer to highs and lows that might have been missed by occasional finger sticks.
What about accuracy?
Understanding the issue of accuracy requires an appreciation of the fact that CGMs don’t work like finger-sticks. Rather than taking glucose readings directly from a drop of blood, CGM readings are taken from interstitial fluid, a thin layer of fluid that surrounds the tissue cells just below the skin.
Calculations are then made to translate the readings into a measurement of glucose.
The hurdle that stands in the way of accuracy is the presence of misleading compounds in the interstitial fluid. Accuracy and interference are inexorably bound together because certain chemicals prevent current devices from recognizing true glucose levels.
This is a complex problem. Currently, the FDA is concerned with the effect of over 40 of these compounds. Some interfering substances cause glucose levels to rise; others to fall. Different substances could also act to offset each other. Or they may compound on top of each other for a more drastic increase or decrease in glucose levels.
With the possibility of 50% interference or more in the interstitial fluid, current devices are saddled with a dangerous margin of error.
Relaunch of Specialty Brand
The heart is central to our existence. A beating heart gives life. And when it stops, life ends.
I’m sure, as you heard our colleagues share their stories, it triggered memories of your own. I’m sure of that because the devastating effects of cardiovascular disease touch just about every person in America.
Millions of people could stand up here and share a story about themselves or a loved one… about a friend or a colleague. When your life is affected by cardiovascular disease, it’s natural and right to have strong feelings of empathy and compassion.
It’s natural and right to want to do something. Many people have that desire. Yet, very, very few people actually are in the position to do something to help.
We are in that unique position to act on our beliefs – to serve patients. Through your actions, you’ve already had a positive effect on one of the most persistent and destructive health issues of our time.
You enlisted physicians to be first adopters… to “write and fight” for their patients. You did it without the benefit of the new data in the label… and against some of the toughest – and often unreasonable – access hurdles our country has ever seen.
Over 250,000 scripts have been written since launch, out of which 63,000 patients were able to get our product. That’s 63,000 lives changed for the better, thanks to your work and tireless commitment.
Now we want to make sure that we’re engaging the customer in ways that make the most sense to that individual physician – by “flexing our approach” to correspond to their mindset and situation.
This is something that many of you are doing intuitively. Now we want to do it systematically and together. So, we created a simple “Adoption Ladder” … that goes from Non-Believer … to Beginner… to Believer. You’ve had success with these physicians in the past. Now we can go even further
Corporate Website
HOME PAGE
headline
Inspired by Hope.
Focused on Prevention.
Powered by Innovation.
TILE 1
headline
About Novavax
body
We are committed to delivering novel products that leverage our innovative proprietary recombinant nanoparticle vaccine technology to prevent a broad range of infectious diseases. We produce vaccine candidates to respond to both known and emerging disease threats efficiently and effectively.
LEADERSHIP QUOTE
headline
We are at the forefront of the fight against infectious disease
body
“Never has our path forward been clearer or the need greater. Our experience developing vaccine candidates for some of the world’s toughest viral threats will use the power of our innovative recombinant nanoparticle vaccine platform, fortified by our Matrix-MTM adjuvant to urgent purpose—to reduce the human toll of vaccine-preventable diseases.”
Stanley Erck
President and Chief Executive Officer
Novavax
TILE 2
eyebrow
Threats continually emerge and evolve
headline
An Agile and Determined Team
body
Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, hardworking, and dedicated, they are driven by a passion to find answers and to solve some of our greatest health challenges.
CTA
Learn About Our Science and Technology
Rare Disease Website
UNMET NEEDS IN LC-FAOD: CHRONIC SYMPTOMS AND ACUTE EPISODES
LC-FAOD present across a broad spectrum, and there remains an unmet clinical need. Many patients still experience lifestyle limitations, as well as significant morbidities and life-threatening complications, such as:
-
Chronic symptoms of fatigue, muscle pain, and weakness
-
Arise or are exacerbated during catabolic situations, such as fasting, illness, and endurance exercise
-
Are chronic and progressive manifestations resulting from prolonged energy deficiency and tissue/vital organs fatty acid accumulation
-
-
Acute episodes that often involve rhabdomyolysis, cardiomyopathy, or hypoketotic hypoglycemia
-
Are usually triggered by illness or fasting, but they may occur spontaneously and unpredictably in some LC-FAOD types, with long-lasting implications
-
May lead to hospitalization, emergency room visits, emergency treatment interventions, and sudden death
-
Despite early detection and management, LC-FAOD mortality rates remain high.
DIMINISHED HEALTH-RELATED QUALITY OF LIFE
Patients with LC-FAOD experience substantially diminished health-related quality of life, with negative impacts on physical, mental/emotional, and social functioning.
Thought Leadership eMagazine
The unprecedented growth in the use of business analytics in healthcare is being driven by the explosion of the volume, variety, and velocity of data. It is a clear opportunity for healthcare organizations to change the conversation with their customers by harnessing Big Data.
Companies like Amazon or Google were “born digital.” Their core business model is based on using big data and analytics to drive business results. Companies like ours may have even greater opportunities for competitive advantage, as we are building on current and cutting-edge analytics to shape our work.
Business analytics is not a substitute for good business judgment. They complement our business acumen and, if leveraged properly, provide more confidence in the interactions we have with customers and the decisions we must all make.
Launch of New Sales Force
NSS Vision
-
We’ve been through a lot of change, but what stays constant is our commitment to address unmet needs in CNS
-
“To be a transformational “best in industry” Neuroscience Specialist Salesforce driven by performance, employee engagement and seen as a valued partner in the eyes of our customers and patients”
-
We have the opportunity and responsibility to take it to next level
Differentiating Capabilities
-
Utilize deep marketing insights in the psychiatry space
-
Enhance clinical competency and account management skills
-
New KOL strategy & medical partnerships
-
First in class patient programs
Performance Enabled by Culture
-
Capabilities set us up for high performance
-
Our “X factor” comes from living our culture to the fullest
-
NSS will be defined by an engaging and inclusive culture whose focus is constantly on the patient and customer
-
If every business decision and interaction is patient and customer-centric, we will be seen as truly collaborative partners in the eyes of our customers
-
No “light between our shoulders” but we each bring different strengths
Winning by Building on Our Foundation
-
We’re here to maximize the opportunity
-
You’ve joined a team that has great momentum
-
Still an incredible trajectory ahead – by helping appropriate patients
